Top Markets
#1 BOOK OF MEME BOOK OF MEME +29.78%
#2 Geodnet Geodnet +26.04%
#3 The Black Bull The Black Bull +25.24%
#4 XPIN Network XPIN Network +23.44%
#5 EXOD EXOD +22.08%
#6 Ore Ore +21.41%
#7 Verus Coin Verus Coin +20.44%
#8 Binance-Peg Bitcoin Cash Binance-Peg Bitcoin Cash +20.08%
#9 Neiro Neiro +19.97%
#10 Bitcoin Cash Bitcoin Cash +19.67%
Coin of the day
BOOK OF MEME BOOK OF MEME
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Apollomics, Inc. Apollomics, Inc.

Apollomics, Inc.

APLM
Clasificación en acciones #25241
Apollomics, Inc., a biotechnology enterprise established in 2015 and... Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
Precio por acción
$23.57
Última sincronización: 2026-08-20
Capitalización bursátil
$51.76M
Cambio (1 día)
-0.08%
Cambio (1 año)
289.59%
País
US
Comercio Apollomics, Inc. (APLM)

Categoría

Healthcare
Ingresos de Apollomics, Inc. (APLM)
Ingresos en Aug 2026 TTM: 0
Según los últimos informes financieros de Apollomics, Inc., los ingresos actuales de la empresa (TTM) son 0. En 2026, la empresa obtuvo unos ingresos de 0 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Apollomics, Inc. desde 2026 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
Not enough data for the provided dates.
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US